Yanez JA - Search Results

1

The role of xenobiotic transporters in ophthalmic drug delivery.

Chemuturi N, Yanez JA. Chemuturi N, et al. Among authors: yanez ja. J Pharm Pharm Sci. 2013;16(5):683-707. doi: 10.18433/j3ww34. J Pharm Pharm Sci. 2013. PMID: 24393552 Free article. Review.

2

Flip-flop pharmacokinetics--delivering a reversal of disposition: challenges and opportunities during drug development.

Yáñez JA, Remsberg CM, Sayre CL, Forrest ML, Davies NM. Yáñez JA, et al. Ther Deliv. 2011 May;2(5):643-72. doi: 10.4155/tde.11.19. Ther Deliv. 2011. PMID: 21837267 Free PMC article. Review.

3

Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Louizos C, Yáñez JA, Forrest ML, Davies NM. Louizos C, et al. Among authors: yanez ja. J Pharm Pharm Sci. 2014;17(1):34-91. J Pharm Pharm Sci. 2014. PMID: 24735761 Free PMC article.

4

Chemotherapy induced gastrointestinal toxicity in rats: involvement of mitochondrial DNA, gastrointestinal permeability and cyclooxygenase -2.

Yáñez JA, Teng XW, Roupe KA, Fariss MW, Davies NM. Yáñez JA, et al. J Pharm Pharm Sci. 2003 Sep-Dec;6(3):308-14. J Pharm Pharm Sci. 2003. PMID: 14738710 Free article.

5

Intestinal lymphatic transport for drug delivery.

Yáñez JA, Wang SW, Knemeyer IW, Wirth MA, Alton KB. Yáñez JA, et al. Adv Drug Deliv Rev. 2011 Sep 10;63(10-11):923-42. doi: 10.1016/j.addr.2011.05.019. Epub 2011 Jun 13. Adv Drug Deliv Rev. 2011. PMID: 21689702 Free PMC article. Review.

6

Multiple peaking phenomena in pharmacokinetic disposition.

Davies NM, Takemoto JK, Brocks DR, Yáñez JA. Davies NM, et al. Among authors: yanez ja. Clin Pharmacokinet. 2010 Jun;49(6):351-77. doi: 10.2165/11319320-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20481648 Review.

7

Stereospecific pharmacokinetics of racemic homoeriodictyol, isosakuranetin, and taxifolin in rats and their disposition in fruit.

Vega-Villa KR, Remsberg CM, Takemoto JK, Ohgami Y, Yáñez JA, Andrews PK, Davies NM. Vega-Villa KR, et al. Among authors: yanez ja. Chirality. 2011 Apr;23(4):339-48. doi: 10.1002/chir.20926. Epub 2010 Nov 10. Chirality. 2011. PMID: 21384439

8

Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(epsilon-caprolactone) micelles of rapamycin.

Yáñez JA, Forrest ML, Ohgami Y, Kwon GS, Davies NM. Yáñez JA, et al. Cancer Chemother Pharmacol. 2008 Jan;61(1):133-44. doi: 10.1007/s00280-007-0458-z. Epub 2007 Mar 29. Cancer Chemother Pharmacol. 2008. PMID: 17393166 Free PMC article.

9

Paclitaxel prodrugs with sustained release and high solubility in poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelle nanocarriers: pharmacokinetic disposition, tolerability, and cytotoxicity.

Forrest ML, Yáñez JA, Remsberg CM, Ohgami Y, Kwon GS, Davies NM. Forrest ML, et al. Among authors: yanez ja. Pharm Res. 2008 Jan;25(1):194-206. doi: 10.1007/s11095-007-9451-9. Epub 2007 Oct 3. Pharm Res. 2008. PMID: 17912488 Free PMC article.

10

Clinical toxicities of nanocarrier systems.

Vega-Villa KR, Takemoto JK, Yáñez JA, Remsberg CM, Forrest ML, Davies NM. Vega-Villa KR, et al. Among authors: yanez ja. Adv Drug Deliv Rev. 2008 May 22;60(8):929-38. doi: 10.1016/j.addr.2007.11.007. Epub 2008 Feb 7. Adv Drug Deliv Rev. 2008. PMID: 18313790 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

66 results

Search Page